ClinicalTrials.gg
Not yet recruitingNCT07847099Updated Sep 29, 2026

Platelet Indices and Blood Groups in Type 2 Diabetes Vascular Complications

An observational study in Type 2 Diabetes Mellitus and Vascular Complications, sponsored by Assiut University. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by Assiut University · Observational

Updated Sep 29, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
100
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 25 studies in Diabetes Mellitus, Type 2 by Assiut University — 15 open to participants now, 15 under way, 1 of them phase 3. Diabetes Mellitus, Type 2 · Assiut University.

Planned enrollment
12th of 23
100 · median 100
Started
2026
with 9 others
Observational
23 of 25
14 open now
Primary completion
2027-09
later than 6 of 14 live
Registered
21st of 25
by date

Among the 25 studies in Diabetes Mellitus, Type 2 by Assiut University, this one is the 12th largest by planned enrollment of the 23 observational ones that give a count, is one of 10 that started in 2026, is one of 23 observational ones, reaches primary completion later than 6 of the 14 other live ones, and was the 21st registered.

Diabetes Mellitus, Type 2

10,382 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

15 of the 25 studies in Diabetes Mellitus, Type 2 by Assiut University are open now, in 1 country. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 15 open studies →

Where they have run

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Diabetes Mellitus, Type 2 by Assiut University, or all of them as a file.
02

Study summary

This cross-sectional study aims to evaluate the association of platelet indices and ABO blood groups with vascular complications in patients with type 2 diabetes mellitus.

Read the detailed description

Vascular complications are a major cause of morbidity in type 2 diabetes mellitus. Platelet indices and ABO blood groups may be related to these complications.

This observational study will include adult patients with type 2 diabetes mellitus. Patients will be classified into those with and without vascular complications. Platelet indices (MPV, PDW) and ABO blood groups will be assessed.

03

Conditions studied

  • Type 2 Diabetes Mellitus
  • Vascular Complications

Keywords

  • Platelet indices
  • MPV
  • Type 2 diabetes
  • ABO blood group
  • Assiut
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients with type 2 diabetes mellitus attending the Internal Medicine Department and Diabetes Center at Assiut University Hospital.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or older
  • Confirmed diagnosis of type 2 diabetes mellitus according to ADA criteria
  • Written

Exclusion criteria

Exclusion Criteria:

  • Type 1 diabetes mellitus
  • Gestational diabetes
  • Acute infection or sepsis
  • Hematological disorders affecting count or function
  • Chronic liver disease
  • diseases
  • Current anticoagulant or antiplatelet therapy
  • Recent major surgery or trauma
  • Pregnancy
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
100 participants (estimated)
Patient registry
No

Groups and cohorts

  • T2DM with Vascular Complications

    Patients with type 2 diabetes mellitus who have microvascular or macrovascular complications.

  • T2DM without Vascular Complications

    Patients with type 2 diabetes mellitus who have no microvascular or macrovascular complications.

06

What researchers measure

Primary outcomes

  1. Mean platelet volume in patients with and without vascular complications

    Mean platelet volume (MPV) in femtoliters compared between type 2 diabetes patients with vascular complications and those without vascular complications.

    Time frame: Baseline

Secondary outcomes

  1. Mean platelet distribution width

    Mean platelet distribution width (PDW) compared between patients with and without vascular complications.

    Time frame: Baseline

  2. Distribution of ABO blood groups according to vascular complications

    Frequency and percentage of ABO blood groups in patients with and without vascular complications.

    Time frame: Baseline

  3. Mean platelet volume according to ABO blood group

    Mean platelet volume (MPV) among different ABO blood groups.

    Time frame: Baseline

  4. Prevalence of microvascular complications

    Proportion of patients with microvascular complications (retinopathy, nephropathy, or neuropathy).

    Time frame: Baseline

  5. Prevalence of macrovascular complications

    Proportion of patients with macrovascular complications (coronary artery disease, cerebrovascular disease, or peripheral arterial disease).

    Time frame: Baseline

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2026; primary completion for Sep 2027, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2026
First posted
Sep 29, 2026
StartEst.
Sep 26, 2026
Primary completionEst.
Sep 26, 2027
CompletionEst.
Mar 25, 2028
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07847099
Lead sponsor
Assiut University
Responsible party
Nehal Sayed Mohammed Sayed (Resident Physician, Department of Internal Medicine, Assiut University) — Principal investigator
First posted
Sep 29, 2026
Start date
Sep 26, 2026 (estimated)
Primary completion
Sep 26, 2027 (estimated)
Completion
Mar 25, 2028 (estimated)
Last update
Sep 29, 2026

Study contacts

Nehla S Mohamed, Resident
Contact
Nehal.18313533@med.aun.edu.eg
01023327969
Lobna F El-toony
study chair · Internal Medicine Department, Assiut University Hospitals

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion